Where Could The Next Breakout for AbbVie Stock Come From

January 6th, 2026 by Trefis Team
ABBV: AbbVie logo
ABBV
AbbVie

AbbVie has demonstrated notable rally potential, with one instance surpassing a 50% gain in under two months in 2020. Additionally, the stock has experienced seven rallies exceeding 30% within similar timeframes, including key years like 2017 and 2024. These powerful surges highlight AbbVie’s capacity for rapid gains, suggesting that future catalysts could drive the stock to significant new highs once again.

Specifically, we see these catalysts:

  1. Immunology Juggernaut: Skyrizi & Rinvoq Exceeding Peak Humira
  2. Neuroscience Franchise Acceleration
  3. Strategic Oncology Tuck-Ins and Pipeline Maturation

Catalyst 1: Immunology Juggernaut: Skyrizi & Rinvoq Exceeding Peak Humira

Relevant Articles
  1. Is Rocket Lab Stock A Buy At $85?
  2. Buy Or Sell Amazon.com Stock?
  3. What’s Happening With SoFi Technologies Stock?
  4. What’s Happening With Intuitive Surgical Stock?
  5. What’s The Upside Potential For Strategy Stock?
  6. How To Earn 9.7% Yield While Waiting to Buy URI 30% Cheaper
  • Details: Combined sales projected to surpass $31 billion by 2027, Driving high-single-digit total revenue growth through 2029,
  • Segment Affected: Immunology
  • Potential Timeline: Ongoing, with major inflection through 2027
  • Evidence: Skyrizi sales up 46%, Rinvoq up 34% in Q3 2025, Management raised 2027 combined sales forecast by $4 billion,

Catalyst 2: Neuroscience Franchise Acceleration

  • Details: Adding over $10 billion in annual revenue, Diversifying revenue base away from immunology,
  • Segment Affected: Neuroscience
  • Potential Timeline: Full Year 2025-2026
  • Evidence: Segment revenues grew 19.6% operationally in Q3 2025, Full-year 2025 revenue guidance for segment raised by $200 million,

Catalyst 3: Strategic Oncology Tuck-Ins and Pipeline Maturation

  • Details: De-risking late-decade pipeline concerns, Potential for multiple new blockbuster revenue streams post-2028,
  • Segment Affected: Oncology
  • Potential Timeline: Deal integration 2026, pipeline readouts 2027-2028
  • Evidence: Recent acquisitions of ImmunoGen and Cerevel, Licensing deal for Alveltamig with Zelgen Biopharma,

But The Stock Is Not Without Its Risks

Here are specific risks we see:

  • Humira Revenue Collapse Accelerating
  • Systemic Margin Erosion via Price Controls
  • Pipeline Fragility Under Immense Pressure

Looking at historical drawdown during market crises is another lens to look at risk.

ABBV fell 45% in the 2018 correction, 34% during the Covid crash, and 22% in the inflation shock. Even strong stocks face sharp dips when markets turn sour.

Read ABBV Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.

Reference: Current Fundamentals

  • Revenue Growth: 7.4% LTM and 1.2% last 3-year average.
  • Cash Generation: Nearly 33.0% free cash flow margin and 24.1% operating margin LTM.
  • Valuation: AbbVie stock trades at a P/E multiple of 163.1

  ABBV S&P Median
Sector Health Care –
Industry Biotechnology –
PE Ratio 163.1 23.8
   
LTM* Revenue Growth 7.4% 6.2%
3Y Average Annual Revenue Growth 1.2% 5.7%
   
LTM* Operating Margin 24.1% 18.8%
3Y Average Operating Margin 27.0% 18.4%
LTM* Free Cash Flow Margin 33.0% 13.5%

*LTM: Last Twelve Months | If you want more details, read Buy or Sell ABBV Stock.

Still not convinced about ABBV stock? Consider Portfolio Approach

Move Beyond Single Stocks With A Multi Asset Portfolio

Single markets are unpredictable but different assets react differently. A multi asset portfolio cuts downside shocks while keeping upside on the table.

The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices